The “vegovi” brand slimming syringe is sold in Achaat Pharmacy in Mittay. The “vegovi” slimming syringe is available in Germany for one year.
Jens Kaline | Picture alliance | Getty images
Novo nordisk Said on Monday that it is ending its cooperation Snow and its Due to concerns about the sales of the telehaalth company and promoting the cheap knock-off of the weight loss drug wagovi.
The shares of HIMS & Hers fell nearly 28% on Monday, while the stock of Novo Nordisk fell more than 6%.
In April, Novo Nordisk said it will happen Offer Vegovi To expand access to access to blockbuster injections such as Hims & Hers blockbuster injections through many telehealth companies No less supply now In America
The end of Wegovy deficiency means that compounding pharmacies were banned from making and selling legally cheaper, until May 22 – unpassited version of the drug – with rare exceptions. Telehealth companies have said that patients may still require individual mixed versions of Vagovi in conditions where it is medically essential.
But Novo Nordisk said on Monday that Himas and Hars have failed to follow the law which prevents the large -scale sales of mixed drugs under the “false barrier” of privatization. The drug manufacturer also accused the hospital of the hospital and its “misleading” marketing which is risking the patient’s safety.
Dave Moore, Executive Vice President of American Operations of Novo Nordisk, CNBC said, “We expected that compounding personalization efforts would be reduced over time. When we did not see this, we had to make an option from the patients,” Dave Moore, Novo Nordisk’s American Operations, Executive Vice President, told CNBC. “We are firm with all that patient safety is our primary focus.”
“We expected [Hims & Hers’] The focus of the business will move towards real, safe, approved drugs, “he said. Moore said
A spokesperson for a Hims and hers did not immediately respond to the CNBC’s remarks request.
During an earning call in May, Andrew Doodam, CEO of Hims and Hers, said that the company prefers providers and patients in their treatment.
“Finally what is right for them is their own conscience,” he said. “I think we strongly believe that it is really important that we maintain that freedom.”
In a note on Monday, City Analyst Daniel Groslate said that the end of cooperation increased the Hims and his “legal risk” to a great extent. ” He said that he was surprising the partnership, when the announcement was initially announced, no attempts were included to curb the compounding efforts of the Telehaalth Company.
during Food and Drug AdministrationPharmacists can legally create mixed versions of brand-name drugs. They can also be produced on the basis of a case-by-case when it is medically necessary for a patient, such as when they cannot swallow a pill or a branded drug is allergic to a specific component.
But drug manufacturers and some health experts have pushed back against practice, roughly because the FDA has not approved mixed drugs.
Novo Nordisk said that it would continue to offer the branded version of Wagovi through telehaalth organizations to “share our commitment for safe and effective medical treatment for patients living with chronic diseases.”
Moore said Novo Nordisk has reduced many other mass compounding pharmacies or stopped making and selling vegovi knock-offs. He said that the company “will be attached to the legal front” and with the FDA to ensure that the illegal compound is reduced.
In a release on Monday, Novo Nordisk stated that it conducted an investigation that found that the active ingredients and mixed pharmacies used in the Vagovi knock-offs sold by telehaalth companies are manufactured by foreign suppliers in China. Drug manufacturer also Cited a report From the Brookings Institution in April, in which it was found that a large part of those Chinese suppliers was never inspected by the FDA, and many were inspected.
Moore said, “These drugs that are coming from sources around the world in our country are not approved even in countries that they originated, and this is a problem.”
